The people building onconephrology
Onconephrology and MGRS are young fields carried by a relatively small community of clinicians and scientists. This page recognizes its leading clinical contributors — ranked by a blend of publication volume and citation impact across 15,329 human/clinical PubMed articles in eight subfields (filtered toward clinical work; see the method notes below) — and maps who works where. Every figure is counted in code from real records; it is a bibliometric measure, not a ranking of merit or influence.
The onconephrology field
Each circle is one recognized contributor, sized by paper count and clustered with the subfield they publish in most.
- Onco-nephrology (general)
- Anticancer drug nephrotoxicity
- Checkpoint-inhibitor kidney injury
- MGRS & paraprotein kidney disease
- Myeloma cast nephropathy
- Anti-VEGF / TKI renal effects
- Tumor lysis & electrolytes
- Cellular therapy renal effects
Most recognized overall
The 30 contributors with the highest blended volume-and-impact score across the whole corpus. Each name links to that author’s PubMed bibliography.
2,767 citations · 2F/13L author · 2008–2026
Leaders by subfield
The most-published contributors within each of the eight onconephrology subfields — so specialists in smaller areas are recognized alongside the high-volume generalists.
Onco-nephrology (general)
339 PubMed matchesThe field named explicitly — reviews, consensus, and cross-cutting work.
- Jhaveri, Kenar DPubMed search for Jhaveri, Kenar D (opens in a new tab)32p in subfield · 1,641c overall
- Perazella, Mark APubMed search for Perazella, Mark A (opens in a new tab)18p in subfield · 2,544c overall
- Rosner, Mitchell HPubMed search for Rosner, Mitchell H (opens in a new tab)15p in subfield · 964c overall
- Izzedine, HassanPubMed search for Izzedine, Hassan (opens in a new tab)14p in subfield · 920c overall
- Kitchlu, AbhijatPubMed search for Kitchlu, Abhijat (opens in a new tab)7p in subfield · 1,547c overall
Anticancer drug nephrotoxicity
8,695 PubMed matchesChemotherapy, targeted agents, and immunotherapy injuring the kidney — this atlas's core.
- Dong, ZhengPubMed search for Dong, Zheng (opens in a new tab)29p in subfield · 3,041c overall
- Perazella, Mark APubMed search for Perazella, Mark A (opens in a new tab)33p in subfield · 2,544c overall
- Gupta, ShrutiPubMed search for Gupta, Shruti (opens in a new tab)23p in subfield · 1,305c overall
- Herrmann, Sandra MPubMed search for Herrmann, Sandra M (opens in a new tab)24p in subfield · 1,531c overall
- Leaf, David EPubMed search for Leaf, David E (opens in a new tab)18p in subfield · 1,861c overall
Checkpoint-inhibitor kidney injury
630 PubMed matchesImmune checkpoint inhibitor–associated acute interstitial nephritis and AKI.
- Herrmann, Sandra MPubMed search for Herrmann, Sandra M (opens in a new tab)22p in subfield · 1,531c overall
- Sise, Meghan EPubMed search for Sise, Meghan E (opens in a new tab)16p in subfield · 1,468c overall
- Leaf, David EPubMed search for Leaf, David E (opens in a new tab)11p in subfield · 1,861c overall
- Abudayyeh, AlaPubMed search for Abudayyeh, Ala (opens in a new tab)15p in subfield · 1,474c overall
- Gupta, ShrutiPubMed search for Gupta, Shruti (opens in a new tab)11p in subfield · 1,305c overall
MGRS & paraprotein kidney disease
4,896 PubMed matchesMonoclonal gammopathy of renal significance and light-chain kidney injury.
- Leung, NelsonPubMed search for Leung, Nelson (opens in a new tab)137p in subfield · 8,809c overall
- Nasr, Samih HPubMed search for Nasr, Samih H (opens in a new tab)73p in subfield · 5,676c overall
- Dispenzieri, AngelaPubMed search for Dispenzieri, Angela (opens in a new tab)82p in subfield · 12,233c overall
- Bridoux, FrankPubMed search for Bridoux, Frank (opens in a new tab)65p in subfield · 4,314c overall
- Gertz, Morie APubMed search for Gertz, Morie A (opens in a new tab)73p in subfield · 5,598c overall
Myeloma cast nephropathy
5,978 PubMed matchesMultiple myeloma and plasma-cell dyscrasias with renal involvement.
- Leung, NelsonPubMed search for Leung, Nelson (opens in a new tab)91p in subfield · 8,809c overall
- Dimopoulos, Meletios APubMed search for Dimopoulos, Meletios A (opens in a new tab)84p in subfield · 9,560c overall
- Dispenzieri, AngelaPubMed search for Dispenzieri, Angela (opens in a new tab)56p in subfield · 12,233c overall
- Terpos, EvangelosPubMed search for Terpos, Evangelos (opens in a new tab)59p in subfield · 7,918c overall
- Kyle, Robert APubMed search for Kyle, Robert A (opens in a new tab)49p in subfield · 9,687c overall
Anti-VEGF / TKI renal effects
1,752 PubMed matchesAnti-angiogenic proteinuria, thrombotic microangiopathy, and glomerular injury.
- Rini, Brian IPubMed search for Rini, Brian I (opens in a new tab)11p in subfield · 1,903c overall
- Pazdur, RichardPubMed search for Pazdur, Richard (opens in a new tab)7p in subfield · 1,824c overall
- Chen, Helen XPubMed search for Chen, Helen X (opens in a new tab)13p in subfield · 3,216c overall
- Izzedine, HassanPubMed search for Izzedine, Hassan (opens in a new tab)11p in subfield · 920c overall
- Kumada, HiromitsuPubMed search for Kumada, Hiromitsu (opens in a new tab)4p in subfield · 636c overall
Tumor lysis & electrolytes
696 PubMed matchesTumor lysis syndrome and cancer-therapy electrolyte disorders affecting the kidney.
- Johnson, Richard JPubMed search for Johnson, Richard J (opens in a new tab)5p in subfield · 851c overall
- Zafrani, LaraPubMed search for Zafrani, Lara (opens in a new tab)6p in subfield · 307c overall
- Azoulay, EliePubMed search for Azoulay, Elie (opens in a new tab)7p in subfield · 337c overall
- Malaguarnera, MarianoPubMed search for Malaguarnera, Mariano (opens in a new tab)5p in subfield · 223c overall
- Mirrakhimov, Aibek EPubMed search for Mirrakhimov, Aibek E (opens in a new tab)3p in subfield · 239c overall
Cellular therapy renal effects
644 PubMed matchesCAR-T and cellular immunotherapy renal complications (CRS-associated AKI).
- Marasco, Wayne APubMed search for Marasco, Wayne A (opens in a new tab)5p in subfield · 444c overall
- Lamers, Cor H JPubMed search for Lamers, Cor H J (opens in a new tab)6p in subfield · 1,091c overall
- Gratama, Jan WPubMed search for Gratama, Jan W (opens in a new tab)4p in subfield · 1,056c overall
- Zheng, JunnianPubMed search for Zheng, Junnian (opens in a new tab)10p in subfield · 321c overall
- Suarez, Eloah RabelloPubMed search for Suarez, Eloah Rabello (opens in a new tab)5p in subfield · 424c overall
How this is measured
Eight renal-scoped PubMed queries define the corpus: onco-nephrology, anticancer drug nephrotoxicity, checkpoint-inhibitor kidney injury, MGRS & paraprotein disease, myeloma cast nephropathy, anti-VEGF/TKI renal effects, tumor-lysis & electrolytes, and cellular-therapy renal effects. Every matching article is retrieved in full (no sampling) and its author list parsed. All counts are tallied in code, never estimated, from real records via the PubMed E-utilities API.
Clinical papers only. Because this is a clinical atlas, recognition counts only human/clinical articles — those carrying the PubMed Humans MeSH heading or a clinical publication type (trial, case report, cohort, guideline, review). Pure preclinical (animal-model or cell-culture) studies are excluded — as far as PubMed’s indexing allows; an animal study indexed under Humans, or a review of animal models, can still pass — so a prolific bench scientist doesn’t outrank the clinicians and pathologists doing patient-facing onconephrology. This run kept 15,329 clinical articles and set aside 5,488 preclinical ones.
Ranking blends volume and impact. Contributors are ordered by a 50/50 blend of publication volume (papers) and citation impact, each normalized to the pool. Impact is a position-weighted sum of the Relative Citation Ratio (RCR, from NIH iCite) — a field- and time-normalized citation metric where 1.0 is the median NIH-funded paper. First (lead) and last (senior) authors get full credit; middle authors a fraction, so the score rewards driving high-impact work, not merely appearing on it. Each paper’s RCR is capped (winsorized at 8× the field median) so a single blockbuster — say a phase-3 oncology trial that merely reports renal side effects — can’t crown its authors; impact measures sustained above-median contribution. We use RCR rather than journal impact factor (proprietary, and a cruder proxy), and we do not compute an h-index — a real one needs each author’s full global bibliography and reliable disambiguation, which these records can’t guarantee.
Known limits. Authors are grouped by surname plus given name; PubMed carries no universal author id, so this deterministic key can occasionally split one person across name variants or merge two who share a name. Corresponding authorship is not reliably machine-extractable, so it is omitted rather than invented. Senior-author credit is withheld on 50+ author consortium papers, and RCR accrues over years, so very recent work contributes mainly through the volume half of the blend. This is recognition of contribution within these queries — not a verdict on scientific merit or influence.
Regenerated from PubMed + NIH iCite on 2026-08-02. Educational content — not medical advice.